NVTR / Nuvectra Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 5)* Nuvectra Corpor

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 5)* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2020 (Date of Eve

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

Monthly Operating Report for the month ended March 31, 2020 as filed with the Bankruptcy Court on April 17, 2020

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

Exhibit 99.1 Monthly Operating Report ACCRUAL BASIS CASE NAME: Nuvectra Corporation CASE NUMBER: 19-43090 JUDGE: Honorable Brenda T. Rhoades UNITED STATES BANKRUPTCY COURT NORTHERN & EASTERN DISTRICTS OF TEXAS REGION 6 MONTHLY OPERATING REPORT MONTH ENDING: February 29 2020 MONTH YEAR IN ACCORDANCE WITH TITLE 28, SECTION 1746, OF THE UNITED STATES CODE, I DECLARE UNDER PENALTY OF PERJURY THAT I HA

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

IN THE UNITED STATES BANKRUPTCY COURT FOR THE EASTERN DISTRICT OF TEXAS SHERMAN DIVISION

Exhibit 99.1 Docket #0263 Date Filed: 3/10/2020 Ryan E. Manns (TX Bar No. 24041391) Toby L. Gerber (TX Bar No. 07813700) Laura L. Smith (TX Bar No. 24066039) Shivani P. Shah (TX Bar No. 24102710) NORTON ROSE FULBRIGHT US LLP 2200 Ross Avenue, Suite 3600 Dallas, Texas 75201-7932 Telephone: (214) 855-8000 Facsimile: (214) 855-8200 Counsel for the Debtor and Debtor In Possession IN THE UNITED STATES

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

NVTR / Nuvectra Corporation / GILDER GAGNON HOWE & CO LLC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 4)* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2019 (Date of Eve

NVTR / Nuvectra Corporation / First Light Asset Management, LLC - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Nuvectra Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

UNITED STATES BANKRUPTCY COURT

Exhibit 99.1 Monthly Operating Report ACCRUAL BASIS CASE NAME: Nuvectra Corporation CASE NUMBER: 19-43090 JUDGE: Honorable Brenda T. Rhoades UNITED STATES BANKRUPTCY COURT NORTHERN & EASTERN DISTRICTS OF TEXAS REGION 6 MONTHLY OPERATING REPORT MONTH ENDING: January 31 2020 MONTH YEAR IN ACCORDANCE WITH TITLE 28, SECTION 1746, OF THE UNITED STATES CODE, I DECLARE UNDER PENALTY OF PERJURY THAT I HAV

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2020 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

IN THE UNITED STATES BANKRUPTCY COURT FOR THE EASTERN DISTRICT OF TEXAS SHERMAN DIVISION

Exhibit 99.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE EASTERN DISTRICT OF TEXAS SHERMAN DIVISION In Re: NUVECTRA CORPORATION,1 Debtor. § § § § § Chapter 11 Case No. 19-43090 ORDER (I) APPROVING BID AND AUCTION PROCEDURES, INCLUDING STALKING HORSE PROTECTIONS; (II) AUTHORIZING AND SCHEDULING AN AUCTION FOR THE SALE OF ASSETS; (III) APPROVING THE SALE OF ASSETS; AND (IV) GRANTING RELATED RELIEF

UNITED STATES BANKRUPTCY COURT

Exhibit 99.1 Monthly Operating Report ACCRUAL BASIS CASE NAME: Nuvectra Corporation CASE NUMBER: 19-43090 JUDGE: Honorable Brenda T. Rhoades UNITED STATES BANKRUPTCY COURT NORTHERN & EASTERN DISTRICTS OF TEXAS REGION 6 MONTHLY OPERATING REPORT MONTH ENDING: December 31 2019 MONTH YEAR IN ACCORDANCE WITH TITLE 28, SECTION 1746, OF THE UNITED STATES CODE, I DECLARE UNDER PENALTY OF PERJURY THAT I HA

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES BANKRUPTCY COURT

Exhibit 99.1 Monthly Operating Report ACCRUAL BASIS CASE NAME: Nuvectra Corporation CASE NUMBER: 19-43090 JUDGE: Honorable Brenda T. Rhoades UNITED STATES BANKRUPTCY COURT EASTERN DISTRICT OF TEXAS REGION 6 MONTHLY OPERATING REPORT MONTH ENDING: November 30 2019 MONTH YEAR IN ACCORDANCE WITH TITLE 28, SECTION 1746, OF THE UNITED STATES CODE, I DECLARE UNDER PENALTY OF PERJURY THAT I HAVE EXAMINED

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Nuvectra® Continuing to Support Current Patients with the Algovita® Implant as Company Voluntarily Files for Chapter 11 Court-Supervised Process Has No Impact on Safety or Functionality of Algovita Device; Company Continuing to Support Physicians

Exhibit 99.1 FOR IMMEDIATE RELEASE Nuvectra® Continuing to Support Current Patients with the Algovita® Implant as Company Voluntarily Files for Chapter 11 Court-Supervised Process Has No Impact on Safety or Functionality of Algovita Device; Company Continuing to Support Physicians PLANO, Texas – November 12, 2019 – Nuvectra Corporation (NASDAQ: NVTR) (“Nuvectra” or the “Company”), a neurostimulati

Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

Nuvectra Submits Chemical Composition and Biocompatibility Data to FDA for Virtis™

Exhibit 99.1 Company Contact: Investor Contact: Nuvectra Corporation The Ruth Group Jennifer Kosharek Tram Bui (214) 474-3107 (646) 536-7035 [email protected] [email protected] Nuvectra Submits Chemical Composition and Biocompatibility Data to FDA for Virtis™ Plano, Texas, October 18, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today annou

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer

Exhibit 99.1 Company Contact: Investor Contact: Nuvectra Corporation The Ruth Group Jennifer Kosharek Tram Bui (214) 474-3107 (646) 536-7035 [email protected] [email protected] Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer Plano, Texas, September 20, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointm

Employment Agreement between Nuvectra Corporation and Ms. Jennifer Kosharek, dated September 16, 2019

Exhibit 10.1 Execution Copy EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between Nuvectra Corporation, a Delaware corporation (the “Company” or “Nuvectra”) and Jennifer Kosharek (“Executive”). In consideration of the below mutual covenants and other good and valuable consideration, the parties agree as follows: 1. Employment Period. The Company shal

Nuvectra® Exploring Strategic Options to Enhance Shareholder Value

Exhibit 99.1 Company Contact: Investor Contact: Nuvectra Corporation The Ruth Group Jennifer Kosharek Tram Bui (214) 474-3107 (646) 536-7035 [email protected] [email protected] Nuvectra® Exploring Strategic Options to Enhance Shareholder Value Plano, Texas, August 26, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced that its Boa

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Nuvectra® Reports Second Quarter 2019 Financial Results

Exhibit 99.1 Company Contact: Investor Contact: Nuvectra Corporation The Ruth Group Jennifer Kosharek Tram Bui (214) 474-3107 (646) 536-7035 [email protected] [email protected] Nuvectra® Reports Second Quarter 2019 Financial Results Plano, Texas, July 31, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the

Sixth Amendment to Loan and Security Agreement, dated July 16, 2019, among Nuvectra Corporation and Oxford Finance LLC and Silicon Valley Bank*

Exhibit 10.2 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 16, 2019, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lende

NVTR / Nuvectra Corporation 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Employer Identification

NVTR / Nuvectra Corporation CORRESP - -

July 23, 2019 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Nuvectra Corporation Registration Statement on Form S-3 (File No. 333-232640) Acceleration Request Requested Date: July 25, 2019 Requested Time: 5:00 p.m. (Eastern Time) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 nvtr201907118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction

NVTR / Nuvectra Corporation S-3 - - FORM S-3

As filed with the Securities and Exchange Commission on July 12, 2019 Registration No.

Form of Senior Indenture

Exhibit 4.5 SENIOR INDENTURE DATED AS OF , 20 BETWEEN NUVECTRA CORPORATION as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page RECITALS 1 ARTICLE I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04

Form of Subordinated Indenture

Exhibit 4.6 SUBORDINATED INDENTURE DATED AS OF , 20 BETWEEN NUVECTRA CORPORATION as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page RECITALS 1 ARTICLE I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01. Definitions 1 Section 1.03. Form of Documents Delivered to Trustee 6 Section 1.04. Acts of Holders; Record Dates 7 Section 1.

Equity Distribution Agreement, dated as of July 12, 2019, between Nuvectra Corporation and Piper Jaffray & Co.

Exhibit 1.2 NUVECTRA CORPORATION EQUITY DISTRIBUTION AGREEMENT July 12, 2019 PIPER JAFFRAY & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Nuvectra Corporation, a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Jaffray &

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fi

Separation and Release Agreement, effective June 27, 2019, by and between Nuvectra Corporation and J. Paul Hanchin

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between J. Paul Hanchin (“Executive”) and Nuvectra Corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive was employed by the Company as President; WHEREAS, Executive signed a Severance Agreement with

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Presentation posted to Company website on June 18, 2019.

Exhibit 99.1

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Jennifer Kosharek Tram Bui (214) 474-3107 (646) 536-7035 [email protected] [email protected] Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval Plano, Texas, June 11, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

NVTR / Nuvectra Corporation SD SD

SD 1 nvtr20190508sd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report May 17, 2019 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification No.) 5830 Granite Parkway, Suite

Nuvectra® Announces Departure of COO & CFO Walter Z. Berger Appoints Jennifer Kosharek as Interim CFO

Exhibit 99.1 Company Contact: Investor Contact: Nuvectra Corporation The Ruth Group Jennifer Kosharek Tram Bui (214) 474-3107 (646) 536-7035 [email protected] [email protected] Nuvectra® Announces Departure of COO & CFO Walter Z. Berger Appoints Jennifer Kosharek as Interim CFO Plano, Texas, May 16, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device compa

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

8-K 1 nvtr201905158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction o

NVTR / Nuvectra Corporation S-8 FORM S-8

As filed with the Securities and Exchange Commission on May 1, 2019 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 nvtr201904308k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of

Nuvectra® Reports First Quarter 2019 Financial Results

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Reports First Quarter 2019 Financial Results Plano, Texas, May 1, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced tod

our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019, filed with the SEC on May 1, 2019;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Employer Identificatio

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 nvtr201904228k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction

Fifth Amendment to Loan and Security Agreement, dated April 22, 2019, among Nuvectra Corporation, Algostim LLC, and Pelvistim LLC and Oxford Finance LLC and Silicon Valley Bank.

Exhibit 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of April 22, 2019, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lend

the portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 5, 2019 that are incorporated by reference into Part III of our Annual Report on Form 10-K for the year ended December 31, 2018;

DEF 14A 1 nvtr20190401def14a.htm FORM DEF 14A SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGEACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board Elects Jane J. Song to the Board of Directors

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board Elects Jane J. Song to the Board of Directors Plano, Texas, March 25, 2019 – Nuvectra Corporation (NASDAQ:

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

Subsidiaries of Nuvectra Corporation*

EXHIBIT 21.1 Subsidiaries of Nuvectra Corporation Subsidiary Jurisdiction of Organization Algostim, LLC Delaware PelviStim Delaware

Fourth Amendment to Loan and Security Agreement, dated February 27, 2019, among Nuvectra Corporation, Algostim, LLC, PelviStim LLC, and Oxford Finance LLC and Silicon Valley Bank*

Exhibit 10.10.4 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of February 27, 2019, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”),

our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 4, 2019;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2018. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-37525 Nuvectra Corporation (Exact n

Executive Employment Agreement, effective February 1, 2019, by and between Nuvectra Corporation and Dr. Fred B. Parks, PhD

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made between Nuvectra Corporation, a Delaware corporation (the “Company” or “Nuvectra”), and Dr. Fred B. Parks, (“Executive”). In consideration of the below mutual covenants and other good and valuable consideration, the parties agree as follows: 1. Employment Period. The Company shall employ Exec

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results Record Fourth Quarter & Full Year 2018 Algovita® Sales of $14.1 million and $47.1 million, Up 36% and 84% YoY Respectively

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results Record Fourth Quarter & Full Year 2018 Algovita® Sales of $14.1 million and $47.1 million, Up 36% and 84%

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 nvtr201902278k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdict

NVTR / Nuvectra Corporation / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 3)* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2018 (Date of Eve

NVTR / Nuvectra Corporation / RTW INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.

NVTR / Nuvectra Corporation / GILDER GAGNON HOWE & CO LLC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv513552sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 2)* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108

NVTR / Nuvectra Corporation / First Light Asset Management, LLC - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Nuvectra Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

NVTR / Nuvectra Corporation / KKR Millennium Fund L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock of Nuvectra Corporation and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filing.

NVTR / Nuvectra Corporation / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* NUVECTRA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer Elects Christopher G. Chavez as a Member of the Board of Directors

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer Elects Christopher G. Chavez as a Member of the Board of Directors Plano, Texas, January 31, 2019 – Nuvectra Cor

Separation and Release Agreement, dated January 31, 2019, by and between Nuvectra Corporation and Scott F. Drees

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Scott F. Drees (“Executive”) and Nuvectra Corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive was employed by the Company as its Chief Executive Officer; WHEREAS, Executive signed an Employ

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2019 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

Nuvectra Provides Update on Virtis™ FDA PMA Submission

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra Provides Update on Virtis™ FDA PMA Submission Plano, Texas, January 29, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a medical device company dedicated to neuromodulati

NVTR / Nuvectra Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G/A 1 NVTRSC13GA1Jan2019.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) NUVECTRA CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 67075N108 (CUSIP Number) DECEMBER 31, 2018 (Date of event which requires filing of this statement) Check the ap

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Material Impairments, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation or Organization) (Co

Stock Purchase Agreement, dated December 31, 2018, between Nuvectra Corporation and NEL Group, Inc.

Exhibit 2.1 STOCK PURCHASE AGREEMENT among NUVECTRA CORPORATION, as Seller and NEL Group, Inc., as Buyer December 31, 2018 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”), dated as of December 31, 2018, is entered into by and among Nuvectra Corporation, a Delaware corporation (“Seller”) and NEL Group, Inc., a Delaware corporation (“Buyer”). Preliminary Statements A. In Fe

Consent and Third Amendment to Loan and Security Agreement, dated December 31, 2018, among Nuvectra Corporation, Algostim, LLC, PelviStim LLC, and Oxford Finance LLC and Silicon Valley Bank (filed as Exhibit 10.1 to our current report on Form 8-K on January 7, 2019, and incorporated herein by reference)

Exhibit 10.1 CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 31, 2018, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “C

Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue

Exhibit 99.2 Company Contacts: Nuvectra Corporation Investor Contacts: The Ruth Group Walter Berger, COO & CFO (214) 474-3102 [email protected] Tram Bui / Brian Johnston (646) 536-7035 / 7028 [email protected] Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue Plano, Texas, January 7, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medi

Nuvectra Announces Divesture of NeuroNexus Subsidiary

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra Announces Divesture of NeuroNexus Subsidiary Plano, Texas, January 2, 2019 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced

Financial Statements and Exhibits, Other Events

8-K 1 nvtr201812118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdict

Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita® Plano, Texas, December 12, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical devi

Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita® Plano, Texas, December 3, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device co

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Nuvectra® Reports Third Quarter 2018 Financial Results Reports Record Algovita® Sales of $12.5 million, Up 98% YoY

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Reports Third Quarter 2018 Financial Results Reports Record Algovita® Sales of $12.5 million, Up 98% YoY Plano, Texas, October 29, 2018 – Nuvectra Corporation (NASDAQ

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

NVTR / Nuvectra Corporation FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Employer Identific

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Warrant to Purchase Common Stock, dated September 28, 2018, issued to Oxford Finance LLC (filed as Exhibit 4.1 to our current report on Form 8-K on October 3, 2018, and incorporated herein by reference)

Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN

Warrant to Purchase Common Stock, dated September 28, 2018, issued to Silicon Valley Bank (filed as Exhibit 4.2 to our current report on Form 8-K on October 3, 2018, and incorporated herein by reference)

Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN

Nuvectra® Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Plano, Texas, September 14, 2018 – Nuvectra Corp

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation or Organization) (C

NUVECTRA CORPORATION 2,825,000 Shares of Common Stock $21.25 per share

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220834 PROSPECTUS SUPPLEMENT (to Prospectus dated October 24, 2017) NUVECTRA CORPORATION 2,825,000 Shares of Common Stock $21.25 per share We are offering 2,825,000 shares of our common stock in this offering. Our common stock is listed on The NASDAQ Global Market under the symbol “NVTR.” On September 11, 2018, the closing price of ou

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 11, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation or Organization) (C

Nuvectra® Announces Pricing of Follow-On Stock Offering

Exhibit 99.2 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Announces Pricing of Follow-On Stock Offering Plano, Texas, September 11, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, annou

Underwriting Agreement, dated September 11, 2018, by and between Nuvectra Corporation and Piper Jaffray & Co., as representative of the several underwriters named therein.

Exhibit 1.1 2,825,000 Shares Nuvectra Corporation Common Stock UNDERWRITING AGREEMENT September 11, 2018 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Nuvectra Corporation, a Delaware corporation (the “Company”) proposes to issue and sell t

Nuvectra® Announces Proposed Follow-On Stock Offering

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra® Announces Proposed Follow-On Stock Offering Plano, Texas, September 11, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announc

Subject to Completion, dated September 11, 2018

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220834 The information in this preliminary prospectus supplement and the accompanying base prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying base prospectus

NVTR / Nuvectra Corporation FORM SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report September 6, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.R.S. Employer Identification No.) 5830 Granite Parkway, Suite 1100 Plano, Texas 750

NVTR / Nuvectra Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

SC 13G 1 NVTR.OSC13GAug2018.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NUVECTRA CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 67075N108 (CUSIP Number) AUGUST 16, 2018 (Date of event which requires filing of this statement) Check the appropriate box to desig

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fi

Presentation posted to the Nuvectra website on August 15, 2018.

Exhibit 99.1

NVTR / Nuvectra Corporation FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Employer Identification

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

Nuvectra™ Reports Second Quarter 2018 Financial Results Reports Record Algovita® Sales of $11.5 million, Up 110% YoY

Exhibit 99.1 Company Contacts: Nuvectra Corporation Investor Contacts: The Ruth Group Walter Berger, COO & CFO (214) 474-3102 [email protected] Tram Bui / Brian Johnston (646) 536-7035 / 7028 [email protected] Nuvectra™ Reports Second Quarter 2018 Financial Results Reports Record Algovita® Sales of $11.5 million, Up 110% YoY Plano, Texas, August 7, 2018 – Nuvectra Corporation (NASDAQ

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

NVTR / Nuvectra Corporation FORM 10-Q/A (Quarterly Report)

10-Q/A 1 nvtr2018071910qa.htm FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0

Financial Statements and Exhibits, Other Events

8-K 1 nvtr201806298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction

Nuvectra Provides Update on FDA and TÜV SÜD Review of Virtis™ PMA and CE Mark Applications

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO (214) 474-3102 Tram Bui / Brian Johnston (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra Provides Update on FDA and TÜV SÜD Review of Virtis™ PMA and CE Mark Applications Plano, Texas, July 2, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation

NVTR / Nuvectra Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NUVECTRA CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 67075N108 (CUSIP Number) JUNE 11, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

NVTR / Nuvectra Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 NUVECTRA CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 67075N108 (CUSIP Number) MAY 10, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which thi

NVTR / Nuvectra Corporation / RTW INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

EX-1 2 ex-1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common stock, $0.001 par value, of Nuvectra Corporation beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties here

Nuvectra™ Reports First Quarter 2018 Financial Results

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra™ Reports First Quarter 2018 Financial Results Plano, Texas, May 2, 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced tod

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File N

First Amendment to Warrant to Purchase Common Stock, dated March 23, 2018, issued to SVB Financial Group (filed as Exhibit 4.2.2 to our quarterly report on Form 10-Q on May 2, 2018, and incorporated herein by reference)

Exhibit 4.2.2 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK THIS FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK (this “Amendment”) is entered into as of March 23, 2018, by and between SVB FINANCIAL GROUP (successor by assignment from Silicon Valley Bank) with an office located at 3003 Tasman Drive, Santa Clara, California 95054 (“SVB” and, together with any successor or permitted assign

NVTR / Nuvectra Corporation FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Employer Identificatio

NVTR / Nuvectra Corporation FORM DEF 14A

SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGEACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definitive Proxy Statement ☐Definitive Additional Materials ☐Soliciting Material under §240.

Amendment No. 2 to the Transition Services Agreement, dated effective as of March 13, 2018, between Nuvectra Corporation and Integer Holdings Corporation

Exhibit 10.1 AMENDMENT NO. 2 TO THE TRANSITION SERVICES AGREEMENT THIS AMENDMENT NO. 2 TO THE TRANSITION SERVICES AGREEMENT (this “Amendment”), dated as of March 13, 2018, amends that certain Transition Services Agreement, dated March 14, 2016, by and between Integer Holdings Corporation (f/k/a Greatbatch, Inc.), having an office at 10000 Wehrle Drive, Clarence, New York 14031 (“Integer”) and Nuve

Entry into a Material Definitive Agreement

8-K 1 nvtr201803168k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction

Presentation posted to the Nuvectra website on March 12, 2018.

Exhibit 99.1

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

NVTR / Nuvectra Corporation FORM S-8

As filed with the Securities and Exchange Commission on March 9, 2018 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Nuvectra™ Reports Fourth Quarter and Full Year 2017 Financial Results Record Quarterly Algovita® Revenue of $10.4 Million

Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra™ Reports Fourth Quarter and Full Year 2017 Financial Results Record Quarterly Algovita® Revenue of $10.4 Million Plano, Texas, March 6, 2018 – Nuvectra Corporation (NA

Subsidiaries of Nuvectra Corporation*

EXHIBIT 21.1 Subsidiaries of Nuvectra Corporation Algostim, LLC PelviStim NeuroNexus Technologies, Inc.

NVTR / Nuvectra Corporation FORM 10-K (Annual Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2017. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-37525 Nuvectra Co

Nuvectra Secures $45 Million Second Amendment to Existing Loan and Security Agreement Agreement Provides Company with Increased Financial Flexibility and Extended Amortization Period

ex105586.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra Secures $45 Million Second Amendment to Existing Loan and Security Agreement Agreement Provides Company with Increased Financial Flexibility and Extended

Warrant to Purchase Common Stock, dated February 16, 2018, issued to Oxford Finance LLC (filed as Exhibit 4.1 to our current report on Form 8-K on February 21, 2018, and incorporated herein by reference)

ex105584.htm Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FOR

Second Amendment to Loan and Security Agreement, dated February 16, 2018, among Nuvectra Corporation, Algostim, LLC, PelviStim LLC and NeuroNexus Technologies, Inc., and Oxford Finance LLC and Silicon Valley Bank (filed as Exhibit 10.1 to our current report on Form 8-K on February 21, 2018, and incorporated herein by reference)

ex105585.htm Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of February 16, 2018, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 nvtr201802208k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of

NVTR / Nuvectra Corporation / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2017 (Date of Eve

NVTR / Nuvectra Corporation / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 dfs174.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NUVECTRA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Entry into a Material Definitive Agreement

nvtr201801308k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorpora

Sublease Modification & Extension Agreement, dated effective as of February 1, 2018, between Nuvectra Corporation and Greatbatch Ltd.

ex103939.htm Exhibit 10.1 SUBLEASE MODIFICATION AND EXTENSION AGREEMENT THIS SUBLEASE MODIFICATION AND EXTENSION AGREEMENT (this ?Agreement?) is made February 1, 2018 (?Effective Date?), by and between GREATBATCH LTD., a New York corporation having an address at 10000 Wehrle Drive, Clarence, New York 14031 (?Sublandlord?) and NUVECTRA CORPORATION (f/k/a QiG Group, LLC), a Delaware corporation, hav

Nuvectra™ Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ex104309.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra? Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares Plano, Texas, February 5, 2018 ? Nu

Other Events

nvtr201802058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation or

Nuvectra™ Announces Proposed Follow-On Stock Offering

ex103989.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra? Announces Proposed Follow-On Stock Offering Plano, Texas, January 31, 2018 ? Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device compa

Nuvectra™ Announces Pricing of Follow-On Stock Offering

ex103990.htm Exhibit 99.2 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra? Announces Pricing of Follow-On Stock Offering Plano, Texas, February 1, 2018 ? Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device com

Underwriting Agreement, dated February 1, 2018, by and between Nuvectra Corporation and Piper Jaffray & Co., as representative of the several underwriters named therein.

ex103986.htm Exhibit 1.1 Execution Version 3,248,750 Shares Nuvectra Corporation Common Stock UNDERWRITING AGREEMENT February 1, 2018 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Nuvectra Corporation, a Delaware corporation (the ?Company?)

NVTR / Nuvectra Corporation FORM 8-K (Current Report)

nvtr20180130b8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2018 Nuvectra Corporation (Exact Name of Issuer as Specified in Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation o

NUVECTRA CORPORATION 2,825,000 Shares of Common Stock $8.00 per share

nvtr20171004s3.htm Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220834 PROSPECTUS SUPPLEMENT (to Prospectus dated October 24, 2017) NUVECTRA CORPORATION 2,825,000 Shares of Common Stock $8.00 per share We are offering 2,825,000 shares of our common stock in this offering. Our common stock is listed on The NASDAQ Global Market under the symbol ?NVTR.? On February 1, 2018, the clo

Subject to Completion, dated January 31, 2018.

424B5 1 nvtr20180129b424b5.htm FORM 424B5 Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220834 The information in this preliminary prospectus supplement and the accompanying base prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus suppl

Nuvectra™ Announces Preliminary Unaudited Fourth Quarter and Full Year 2017 Revenue

ex102740.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Tram Bui / Brian Johnston (214) 474-3102 (646) 536-7035 / 7028 [email protected] [email protected] Nuvectra? Announces Preliminary Unaudited Fourth Quarter and Full Year 2017 Revenue Plano, Texas, January 8, 2018 ? Nuvectra Corporation (NASDAQ: NVTR), a neurosti

Presentation posted to the Nuvectra website on January 8, 2018

Image Exhibit Exhibit 99.2

NVTR / Nuvectra Corporation FORM 8-K (Current Report)

nvtr201801058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporat

CORPORATE PARTICIPANTS

ex101261.htm Exhibit 99.1 CORPORATE PARTICIPANTS Matt O?Brien, Piper Jaffray Scott Drees, Chief Executive Officer Walter Berger, Chief Operating Officer and Chief Financial Officer PRESENTATION Matt O?Brien: Matt O?Brien, I cover Medtech here at Piper Jaffray. Thanks so much for joining us. We?ve got the Nuvectra management team here and it?s a story that I think is completely underappreciated and

Current Report

8-K 1 nvtr201711308k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdict

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 nvtr201710318k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdicti

Nuvectra™ Reports Third Quarter 2017 Financial Results Record Quarterly Algovita Revenues, Increasing to $6.3 Million

ex98324.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Zack Kubow / Brian Johnston (214) 474-3102 (646) 536-7020/7028 [email protected] [email protected] Nuvectra? Reports Third Quarter 2017 Financial Results Record Quarterly Algovita Revenues, Increasing to $6.3 Million Plano, Texas, November 1, 2017 ? Nuvectra Corp

NVTR / Nuvectra Corporation FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Employer Identific

NVTR / Nuvectra Corporation CORRESP - -

October 20, 2017 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Tom Jones Re: Nuvectra Corporation Registration Statement on Form S-3 (File No. 333-220834) Acceleration Request Requested Date: October 24, 2017 Requested Time: 4:00 p.m. (Eastern Time) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Secu

Nuvectra FORM S-3

nvtr20171004s3.htm As filed with the Securities and Exchange Commission on October 5, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUVECTRA CORPORATION (Exact name of registrant as specified in its charter) Delaware 30-0513847 (State or other jurisdiction of incorporation or organ

Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission

Warrant to Purchase Common Stock, dated September 28, 2017, issued to Oxford Finance LLC (filed as Exhibit 4.1 to our current report on Form 8-K on October 3, 2017, and incorporated herein by reference)

ex96181.htm Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

nvtr201709018k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporat

Amended and Restated Development Agreement, dated August 31, 2017, between Nuvectra Corporation and Aleva Neurotherapeutics SA. (filed as Exhibit 10.1 to our current report on Form 8-K on September 5, 2017, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 AMENDED AND RESTATED DEVELOPMENT AGREEMENT August, 2017 This Amended Development Agreement (?Agreement?), dated as of 31 Aug 2017 (the ?Effective Date?), is by and between Nuvectra Corp., located at 5830 Granite Parkway; 11th Floor; Plano, TX 75024, USA (?Nuvectra?), and Aleva Neurotherapeutics S.A., located at EPFL Innovation Park, Building D, 1015 Lausanne, Switzerland (?

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

nvtr201708228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporat

Amendment No. 1 to the Supply Agreement, fully executed on August 21, 2017 and effective as of July 21, 2017, between Nuvectra Corporation and Greatbatch Ltd (filed as Exhibit 10.1 to our current report on Form 8-K on August 23, 2017, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this ?Amendment?), dated as of July 21, 2017, amends that certain Supply Agreement (the ?Supply Agreement?), effective the 14th day of March, 2016, between Greatbatch Ltd., having an office at 10000 Wehrle Drive, Clarence, New York 14031 (?Greatbatch?) and Nuvectra Corporation (f/k/a QIG G

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201708028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporati

Nuvectra™ Reports Second Quarter 2017 Financial Results Record Quarterly Algovita® Revenues, Increasing 62% Sequentially

ex99-1.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, COO & CFO Zack Kubow (214) 474-3102 (646) 536-7020 [email protected] [email protected] Jennifer Armstrong, Media Relations Brian Johnston (214) 474-3110 (646) 536-7028 [email protected] [email protected] Nuvectra? Reports Second Quarter 2017 Financial Result

NVTR / Nuvectra Corporation FORM 10-Q (Quarterly Report)

10-Q 1 nvtr2017063010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorpora

Business Property Lease Agreement, dated July 1, 2017, between Neuronexus Technologies, Inc. and BMT Ann Arbor, LLC (filed as Exhibit 10.1 to our current report on Form 8-K on June 30, 2017, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 BUSINESS PROPERTY LEASE BMT Ann Arbor, LLC an Ohio Limited Liability Company (hereinafter referred to as "LESSOR") does, subject to the terms, conditions and agreements set forth below, hereby lease to NeuroNexus Technologies, Inc., a(n) Michigan corporation (hereinafter referred to as "LESSEE"), the following-described property (hereinafter referred to as the "Premises"):

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Amendment to the Development Agreement, dated June 19, 2017, between Nuvectra Corporation and Aleva Neurotherapeutics SA (filed as Exhibit 10.1 to our current report on Form 8-K on June 21, 2017, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 SECOND AMENDMENT TO THE DEVELOPMENT AGREEMENT This Second Amendment (the ?Amendment No. 2?) dated as of June 19, 2017 (the ?Amendment Effective Date?) to the Development Agreement, is by and between Nuvectra Corporation (f/k/a QIG Group, LLC), located at 5830 Granite Parkway, Suite 1100, Plano, TX 75223 (?Nuvectra?), and Aleva Neurotherapeutics S.A., located at EPFL Innovat

EX-99.1

Exhibit 99.1

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr20170523b8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporatio

Nuvectra FORM 10-Q (Quarterly Report)

nvtr2017033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Em

Financial Statements and Exhibits, Results of Operations and Financial Condition

nvtr201705058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation)

Nuvectra™ Reports First Quarter 2017 Financial Results

ex99-1.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Operating Officer and Chief Financial Officer Nick Laudico (214) 474-3102 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Kubow (214) 474-3110 (646) 536-7020 [email protected] [email protected] Nuvectra? Repor

Nuvectra FORM S-8

nvtr20170505s8.htm As filed with the Securities and Exchange Commission on May 9, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nuvectra Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 30-051

Nuvectra FORM DEF 14A

SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGEACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definitive Proxy Statement ☐Definitive Additional Materials ☐Soliciting Material under §240.

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201704038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporati

Amendment to the Development Agreement, dated March 30, 2017, between Nuvectra Corporation and Aleva Neurotherapeutics SA (filed as Exhibit 10.1 to our Current Report on Form 8-K on April 4, 2017, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 AMENDMENT TO THE DEVELOPMENT AGREEMENT This amendment (the ?Amendment?) dated as of March 30, 2017 (the ?Amendment Effective Date?) to the Development Agreement, is by and between Nuvectra Corporation (f/k/a QIG Group, LLC), located at 5830 Granite Parkway, Suite 1100, Plano, TX 75223 (?Nuvectra?), and Aleva Neurotherapeutics S.A., located at EPFL Innovation Park, Building

Nuvectra FORM 10-K (Annual Report)

nvtr2016123110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 30, 2016. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-37525 Nuvectra

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201703068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporatio

Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results

ex99-1.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Operating Officer and Chief Financial Officer Nick Laudico (214) 474-3102 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Kubow (214) 474-3110 (646) 536-7020 [email protected] [email protected] Nuvectra? Repor

Nuvectra Extends Timeline of Existing Credit Facility

ex99-1.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Operating Officer and Chief Financial Officer Nick Laudico (214) 474-3102 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Kubow (214) 474-3110 (646) 536-7020 [email protected] zkubow@theruthgro

First Amendment to Loan and Security Agreement, dated February 14, 2017, among Nuvectra Corporation, Algostim, LLC, PelviStim LLC and NeuroNexus Technologies, Inc., and Oxford Finance LLC and Silicon Valley Bank (filed as Exhibit 10.1 to our current report on Form 8-K on February 14, 2017, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of February 14, 2017, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Age

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201702138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorpor

NVTR / Nuvectra Corporation / GILDER GAGNON HOWE & CO LLC - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No.)* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2016 (Date of Event

JOINT FILING AGREEMENT

EX-1 2 a17-40504ex1.htm EX-1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common stock of Nuvectra Corporation and further agree that this Joint Filing Agreement sha

POWER OF ATTORNEY

EX-2 3 a17-40504ex2.htm EX-2 Exhibit 2 POWER OF ATTORNEY Know all men by these presents that Henry R. Kravis does hereby make, constitute and appoint William J. Janetschek, David J. Sorkin, Terence P. Gallagher, and Christopher B. Lee, or any one of them, as a true and lawful attorney-in-fact of the undersigned with full powers of substitution and revocation, for and in the name, place and stead o

NVTR / Nuvectra Corporation / KKR Millennium Fund L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nuvectra Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

NVTR / Nuvectra Corporation / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NUVECTRA CORP (Name of Issuer) Common Stock (Title of Class of Securities) 67075N108 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201701138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2017 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorpora

Executive Employment Agreement between Nuvectra Corporation and Mr. Walter Berger, dated January 13, 2017 (filed as Exhibit 10.2 to our current report on Form 8-K on January 17, 2017, and incorporated herein by reference) †

ex10-2.htm Exhibit 10.2 Execution Copy (12/30/16) EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made between Nuvectra Corporation, a Delaware corporation (the ?Company? or ?Nuvectra?) and Walter Z. Berger (?Executive?). In consideration of the below mutual covenants and other good and valuable consideration, the parties agree as follows: 1. Employment Per

Executive Employment Agreement between Nuvectra Corporation and Mr. Scott Drees, dated January 13, 2017 (filed as Exhibit 10.1 to our current report on Form 8-K on January 17, 2017, and incorporated herein by reference) †

ex10-1.htm Exhibit 10.1 Execution Copy EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made between Nuvectra Corporation, a Delaware corporation (the ?Company? or ?Nuvectra?), and Scott F. Drees (?Executive?). In consideration of the below mutual covenants and other good and valuable consideration, the parties agree as follows: 1. Employment Period. The Com

First Amendment to Business Agreement, dated April 10, 2010, between QiG Group, LLC and Minnetronix, Inc. (filed as Exhibit 10.4 to our current report on Form 8-K on December 12, 2016, and incorporated herein by reference)

ex10-4.htm Exhibit 10.4 FIRST AMENDMENT TO BUSINESS AGREEMENT THIS FIRST AMENDMENT TO BUSINESS AGREEMENT (the ?Amendment?) is made and entered into as of the 10th day of April, 2010 (?Effective Date?) by and between MINNETRONIX, INC., a Minnesota corporation, (?Minnetronix?) and QIG GROUP, LLC., a Delaware limited liability company, (?Client?) and amends the Business Agreement between the parties

Business Agreement, dated April 30, 2009, between QiG Group, LLC and Minnetronix, Inc. (filed as Exhibit 10.2 to our current report on Form 8-K on December 12, 2016, and incorporated herein by reference)

ex10-2.htm Exhibit 10.2 BUSINESS AGREEMENT This business agreement is dated as of April 30th, 2009 (?Effective Date?), and is between MINNETRONIX, INC., a Minnesota corporation (?Minnetronix?), and QIG GROUP, LLC, a Delaware limited liability company (?Client?). WHEREAS, Minnetronix has experience and expertise in contract design and manufacturing of electronic, software, and mechanical assemblies

Manufacturing and Supply Amendment, dated December 9, 2016, between Nuvectra Corporation and Minnetronix, Inc. (filed as Exhibit 10.1 to our current report on Form 8-K on December 12, 2016, and incorporated herein by reference)

ex10-1.htm CONFIDENTIAL TREATMENT REQUESTED Exhibit 10.1 MANUFACTURING AND SUPPLY AMENDMENT This Manufacturing and Supply Amendment (?Manufacturing Amendment?) is made effective as of December 9, 2016 (the ?Manufacturing Amendment Effective Date?), between Nuvectra Corporation having an office at 5830 Granite Parkway, Suite 1100, Plano, TX 75024 (?Client?) and Minnetronix, Inc., having an office a

NUVECTRA CORPORATION SIGNS DIRECT SUPPLY AGREEMENT Nuvectra Signs Direct Supply Agreement with Minnetronix, Inc. for External Devices

ex99-1.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Financial Officer Nick Laudico (972) 668-4106 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Zubow (214) 474-3110 (646) 536-7020 [email protected] [email protected] NUVECTRA CORPORATION

Manufacturing and Quality Addendum, dated August 1, 2013, between QiG Group, LLC and Minnetronix, Inc. (filed as Exhibit 10.5 to our current report on Form 8-K on December 12, 2016, and incorporated herein by reference)

ex10-5.htm Exhibit 10.5 MANUFACTURING AND QUALITY ADDENDUM This Manufacturing and Quality Addendum (?Addendum?) is made effective as of August 1, 2013 (the ?Addendum Effective Date?), between QIG Group, LLC, having an office at 10000 Wehrle Drive, Clarence, NY 14031 (?Client?) and Minnetronix, Inc., having an office at 1635 Energy Park Drive, St. Paul, MN 55108 (?Minnetronix?) and amends and suppl

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

Letter Agreement, dated June 29, 2009, between QiG Group, LLC and Minnetronix, Inc. (filed as Exhibit 10.3 to our current report on Form 8-K on December 12, 2016, and incorporated herein by reference)

ex10-3.htm Exhibit 10.3 1635 Energy Park DriveSt. Paul, MN 55108-2703 Tel: 651-917-4060 Fax: 651-917-4066 June 26, 2009 Tony Borowicz QiG Group, LLC 10000 Wehrle Drive Clarence, NY 14031 Re: Business Agreement by and between Minnetronix, Inc. (?Minnetronix?) and QiG Group, LLC (?Client?) dated April 30, 2009 (?Business Agreement?). Dear Mr. Borowicz: This letter agreement supplements the Business

Financial Statements and Exhibits

8-K 1 nvtr201611158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 (State or Other Jurisdiction of Inco

EX-99.1

Exhibit 99.1

Nuvectra FORM 10-Q (Quarterly Report)

nvtr2016083010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission F

Nuvectra Reports Third Quarter 2016 Financial Results Continued Progress Building U.S. Sales Organization and Market Awareness of Algovita® System

ex99-1.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Financial Officer Nick Laudico (214) 474-3102 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Kubow (214) 474-3110 (646) 536-7020 [email protected] [email protected] Nuvectra Reports Third Quarter 2016 Financi

Nuvectra FORM 10-Q (Quarterly Report)

nvtr2016070110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2016 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of Incorporation) (I.R.S. Empl

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201608098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporat

Nuvectra Reports Second Quarter 2016 Financial Results Accelerating U.S. Sales Team Build and Initiated Algovita® Sales in the U.S.

ex99-1.htm Exhibit 99.1 Company Contacts: Nuvectra Corporation Investor Contacts: The Ruth Group Walter Berger, Chief Financial Officer Nick Laudico (214) 474-3102 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Kubow (214) 474-3110 (646) 536-7020 [email protected] [email protected] Nuvectra Reports Second Quarter 2016 Financ

Nuvectra FORM 8-K (Current Report/Significant Event)

nvtr201607298k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporati

Cautionary Note Regarding Forward-Looking Statements

ex99-1.htm Exhibit 99.1 Cautionary Note Regarding Forward-Looking Statements This transcript contains "forward-looking statements," including statements we make regarding the outlook for Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 nvtr201606158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction

License Agreement, dated June 14, 2016, between Nuvectra Corporation and Aleva Neurotherapeutics S.A. (filed as Exhibit 10.1 to our current report on Form 8-K on June 17, 2016, and incorporated herein by reference)

ex10-1.htm Exhibit 10.1 LICENSE AGREEMENT This LICENSE AGREEMENT (the ?License Agreement?), dated June 14, 2016 (the ?Effective Date?), is by and between NUVECTRA CORPORATION, a corporation and existing under the laws of the State of Delaware (hereinafter referred to as ?Licensor?) and Aleva Neurotherapeutics SA, a Swiss share company registered under the federal identification number CHE-114.416.

NVTR / Nuvectra Corporation 10-Q - Quarterly Report - FORM 10-Q

nvtr2016040110q.htm Table Of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 1, 2016 Commission File Number 001-37525 Nuvectra Corporation (Exact name of Registrant as specified in its charter) Delaware 30-0513847 (State of (I.R.S.

Nuvectra Reports First Quarter 2016 Financial Results

ex99-1.htm Exhibit 99.1 Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Financial Officer Nick Laudico (214) 474-3102 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Kubow (214) 474-3110 (646) 536-7020 [email protected] [email protected] Nuvectra Reports First Quarter 2016 Financi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 nvtr201604068k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction

NUVECTRA CORPORATION LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

kaulapoa.htm Exhibit 24 NUVECTRA CORPORATION LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby constitutes and appoints each of Walter Berger, Melissa Beare, and Jennifer Kosharek, or either of them acting singly and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. execute for and on beha

NUVECTRA CORPORATION APPOINTS PAUL HANCHIN AS COMPANY PRESIDENT Nuvectra Announces Changes to Executive Management Team

ex99-1.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Company Contacts: Investor Contacts: Nuvectra Corporation The Ruth Group Walter Berger, Chief Financial Officer Nick Laudico (972) 668-4106 (646) 536-7030 [email protected] [email protected] Jennifer Armstrong, Media Relations Zack Zubow (214) 618-4823 (646) 536-7020 [email protected] [email protected] NUVECTRA CORPORATION

NUVECTRA CORPORATION LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

hanchinpoa.htm Exhibit 24 NUVECTRA CORPORATION LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby constitutes and appoints each of Walter Berger, Melissa Beare, and Jennifer Kosharek, or either of them acting singly and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. execute for and on be

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporation) (Commission Fil

EX-99.1

Exhibit 99.1

Certificate of Incorporation (filed as Exhibit 3.1 to our Current Report on Form 8-K on March 18, 2016, and incorporated herein by reference)

ex3-1.htm Exhibit 3.1 CERTIFICATE OF INCORPORATION OF NUVECTRA CORPORATION The undersigned, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware (particularly the General Corporation Law of the State of Delaware, or any applicable successor the

CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION QIG GROUP, LLC Pursuant to Section 265 of the General Corporation Law of the State of Delaware and Section 18-216 of the Delaware Limited Liability Company Act

ex3-3.htm Exhibit 3.3 CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION OF QIG GROUP, LLC Pursuant to Section 265 of the General Corporation Law of the State of Delaware and Section 18-216 of the Delaware Limited Liability Company Act QIG Group, LLC, a Delaware limited liability company (the “Limited Liability Company”), does hereby certify to the following facts relating

PRELIMINARY AND SUBJECT TO COMPLETION, DATED FEBRUARY 24, 2016 INFORMATION STATEMENT Nuvectra Corporation

ex99.1.htm Exhibit 99.1 Information contained herein is subject to completion or amendment. A Registration Statement on Form 10 relating to these securities has been filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. PRELIMINARY AND SUBJECT TO COMPLETION, DATED FEBRUARY 24, 2016 INFORMATION STATEMENT Nuvectra Corporation We are providing this i

NUVECTRA CORPORATION BEGINS TRADING ON NASDAQ Spin-off from Greatbatch creates new stand-alone neurostimulation company

Exhibit 99.2 FOR IMMEDIATE RELEASE Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (972) 668-4106 [email protected] Jennifer Armstrong, Media Relations (214) 618-4823 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Zubow (646) 536-7020 [email protected] NUVECTRA CORPORATION BEGINS TRAD

Bylaws of Nuvectra Corporation (filed as Exhibit 3.2 to our Current Report on Form 8-K on March 18, 2016, and incorporated herein by reference)

ex3-2.htm Exhibit 3.2 BY-LAWS OF NUVECTRA CORPORATION (as of March 14, 2016) ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Nuvectra Corporation (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The Corporation’s board of directors

Employee Matters Agreement, dated March 14, 2016, between Greatbatch, Inc. and QiG Group, LLC (filed as Exhibit 10.3 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.3 EMPLOYEE MATTERS AGREEMENT between GREATBATCH, INC. and QIG GROUP, LLC (to be converted into Nuvectra Corporation) dated as of March 14, 2016 Table of Contents PAGE Article I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Interpretation 4 Article II ASSIGNMENT OF EMPLOYEES 6 Section 2.1 Active Employees 6 Section 2.2 Former Employees 7 Section 2.3 Employment Law Obligations 7 Sec

Restricted License Agreement, dated March 14, 2016, between Greatbatch Ltd. and QiG Group, LLC (filed as Exhibit 10.6 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.6 RESTRICTED LICENSE AGREEMENT This RESTRICTED LICENSE AGREEMENT (the ?License Agreement?), dated March 14, 2016 (the ?Effective Date?), is by and between QIG GROUP, LLC, a Delaware limited liability company (hereinafter referred to as ?Licensor?) and GREATBATCH LTD., a New York corporation (hereinafter referred to as ?Licensee?). The Licensor and the Licensee are sometimes referred to

Agreement of Sublease, dated March 14, 2016, between Greatbatch Ltd. and QiG Group, LLC (filed as Exhibit 10.9 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.9 AGREEMENT OF SUBLEASE THIS AGREEMENT OF SUBLEASE (the ?Sublease?), made as of the 14th day of March, 2016, by and between GREATBATCH LTD., a New York corporation, whose business address is 10000 Wehrle Drive, Clarence, New York 14031 (?Sublandlord?), and QiG GROUP, LLC, a Delaware limited liability company, whose business address is 5830 Granite Parkway, 11th Floor, Plano, Texas 75024

License Agreement, dated March 13, 2016, between Greatbatch Ltd. and NeuroNexus Technologies, Inc. (filed as Exhibit 10.8 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

EX-10.8 15 ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 LICENSE AGREEMENT This LICENSE AGREEMENT (the “License Agreement”), dated March 13, 2016 (the “Effective Date”), is by and between NEURONEXUS TECHNOLOGIES, INC., a Michigan corporation (hereinafter referred to as “Licensor”) and GREATBATCH LTD., a New York corporation (hereinafter referred to as “Licensee”). The Licensor and the Licensee are sometime

Product Component and Framework Agreement, dated March 14, 2016, between Greatbatch Ltd. and QiG Group, LLC (filed as Exhibit 10.5 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.5 PRODUCT COMPONENT FRAMEWORK AGREEMENT This PRODUCT COMPONENT FRAMEWORK AGREEMENT (the ?Agreement?), effective the 14th day of March, 2016 (the ?Effective Date?) is by and between Greatbatch Ltd., a New York corporation, located at 10000 Wehrle Drive, Clarence, New York, 14031, (?Greatbatch?) and QiG Group, LLC, a Delaware limited liability company, located at 5700 Granite Parkway, Sui

NUVECTRA CORPORATION 2016 EQUITY INCENTIVE PLAN

Exhibit 10.12 NUVECTRA CORPORATION 2016 EQUITY INCENTIVE PLAN 1 PURPOSE The name of this plan is the Nuvectra Corporation 2016 Equity Incentive Plan (as it may be amended from time to time, the ?Plan?). This Plan was adopted by the Board of Managers of QiG Group, LLC in expectation of the Spin-off (as defined below) and QiG Group, LLC?s conversion from a Delaware limited liability company to a Del

Tax Matters Agreement, dated March 14, 2016, between Greatbatch, Inc. and QiG Group, LLC (filed as Exhibit 10.2 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.2 TAX MATTERS AGREEMENT between GREATBATCH, INC. and QIG GROUP, LLC (to be converted into NUVECTRA CORPORATION) dated as of March 14, 2016 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND EXAMPLES Section 1.1 Definitions 1 ARTICLE II ALLOCATION OF TAXES AND TAX ITEMS 6 Section 2.1 General Rules 6 (a) GB Taxes 6 (b) Nuvectra Taxes 6 Section 2.2 Special Rules 7 (a) Pro Forma Stand-Alone B

Loan and Security Agreement, dated March 18, 2016, among Oxford Finance, LLC, Silicon Valley Bank, Nuvectra Corporation, Algostim, LLC, PelviStim LLC and NeuroNexus Technologies, Inc. (filed as Exhibit 10.11 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

ex10-11.htm Exhibit 10.11 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of March 18, 2016 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as colla

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2016 Nuvectra Corporati

nuve201603118k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2016 Nuvectra Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-37525 30-0513847 (State or Other Jurisdiction of Incorporati

Form of Nonqualified Stock Option Agreement – Non-Employee Director (filed as Exhibit 10.15 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)†

Exhibit 10.15 NUVECTRA CORPORATION 2016 EQUITY INCENTIVE PLAN FORM OF NONQUALIFIED STOCK OPTION AGREEMENT ? NON-EMPLOYEE DIRECTORS This NONQUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) is made and entered into as of the date of grant set forth below (the ?Date of Grant?) by and between Nuvectra Corporation, a Delaware corporation (the ?Company?), and the individual named below (the ?Optionee

Form of Nonqualified Stock Option Agreement – Employee (filed as Exhibit 10.13 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)†

Exhibit 10.13 NUVECTRA CORPORATION 2016 EQUITY INCENTIVE PLAN FORM OF NONQUALIFIED STOCK OPTION AGREEMENT ? EMPLOYEES This NONQUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) is made and entered into as of the date of grant set forth below (the ?Date of Grant?) by and between Nuvectra Corporation, a Delaware corporation (the ?Company?), and the individual named below (the ?Optionee?). Capitaliz

Office Lease, dated December 2, 2015, by and between EOS Development 1 LLC and Greatbatch Ltd., as assigned by Greatbatch Ltd. to Nuvectra Corporation on March 14, 2016 (filed as Exhibit 10.10 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.10 Execution Version OFFICE LEASE by and between EOS DEVELOPMENT 1 LLC, a Delaware limited liability company as LANDLORD and GREATBATCH LTD., a New York corporation as TENANT EOS AT INTERLOCKEN 105 EDGEVIEW DRIVE BROOMFIELD, COLORADO SUITE 310 December 2, 2015 1. LEASED PREMISES 1 2. TERM 2 3. RENT 2 4. SECURITY DEPOSIT 2 5. USE 3 6. OPERATING EXPENSES 5 7. UTILITIES AND SERVICES 11 8.

Transition Services Agreement, dated March 14, 2016, between Greatbatch, Inc. and QiG Group, LLC (filed as Exhibit 10.1 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

EX-10.1 8 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 TRANSITION SERVICES AGREEMENT BETWEEN GREATBATCH, INC. and QIG GROUP, LLC (to be converted into NUVECTRA CORPORATION) Dated March 14, 2016 table of contents Page No. ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 ARTICLE II TRANSITION SERVICES 2 Section 2.1 Transition Services 2 Section 2.2 Service Coordinators 3 Section 2.3 Additional Transition S

Form of Restricted Stock Unit Agreement – Employee (filed as Exhibit 10.14 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)†

ex10-12.htm Exhibit 10.14 NUVECTRA CORPORATION 2016 EQUITY INCENTIVE PLAN FORM OF RESTRICTED STOCK UNIT AGREEMENT - EMPLOYEES This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Nuvectra Corporation, a Delaware corporation (the “Company”), and the individual named below (“Grantee”). Capitalize

DIRECTOR INDEMNIFICATION AGREEMENT

Exhibit 10.17 DIRECTOR INDEMNIFICATION AGREEMENT This Director Indemnification Agreement, dated as of (this ?Agreement?), is made by and between Nuvectra Corporation, a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS: A. Section 141 of the General Corporation Law of the State of Delaware provides that the business and affairs of a corporation shall be managed by or under the dir

Supply Agreement, dated March 14, 2016, between Greatbatch Ltd. and QiG Group, LLC (filed as Exhibit 10.4 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.4 Confidential Treatment Requested SUPPLY AGREEMENT This SUPPLY AGREEMENT (the ?Agreement?), effective the 14th day of March, 2016 (the ?Effective Date?) is between Greatbatch Ltd., located at 10000 Wehrle Drive, Clarence, New York 14031, (?Greatbatch?) and QiG Group, LLC, a Delaware limited liability company, located at 5700 Granite Parkway, Suite 960, Plano, Texas, 75024 (?QiG Group?)

Warrant to Purchase Common Stock, dated March 18, 2016, issued to Oxford Finance LLC (filed as Exhibit 4.1 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

ex1-new1012.htm Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN

Warrant to Purchase Common Stock, dated March 18, 2016, issued to Silicon Valley Bank (filed as Exhibit 4.2 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

ex4-1.htm Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE

SEPARATION AND DISTRIBUTION AGREEMENT GREATBATCH, INC. QIG GROUP, LLC (to be converted into Nuvectra Corporation) dated as of March 14, 2016 TABLE OF CONTENTS

ex2-1.htm Exhibit 2.1 EXECUTION VERSION SEPARATION AND DISTRIBUTION AGREEMENT between GREATBATCH, INC. and QIG GROUP, LLC (to be converted into Nuvectra Corporation) dated as of March 14, 2016 TABLE OF CONTENTS Page(s) ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Interpretation 11 ARTICLE II SEPARATION AND RELATED TRANSACTIONS 13 Section 2.1 The Separation 13 Section 2.2 Charter a

Unrestricted License Agreement, dated March 14, 2016, between Greatbatch Ltd. and QiG Group, LLC (filed as Exhibit 10.7 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)

Exhibit 10.7 UNRESTRICTED LICENSE AGREEMENT This UNRESTRICTED LICENSE AGREEMENT (the ?License Agreement?), dated March 14, 2016 (the ?Effective Date?), is by and between QIG GROUP, LLC, a Delaware limited liability company (hereinafter referred to as ?Licensor?) and GREATBATCH LTD., a New York corporation (hereinafter referred to as ?Licensee?). The Licensor and the Licensee are sometimes referred

OFFICer INDEMNIFICATION AGREEMENT

Exhibit 10.18 OFFICer INDEMNIFICATION AGREEMENT This Officer Indemnification Agreement, dated as of (this ?Agreement?), is made by and between Nuvectra Corporation, a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS: A. Pursuant to Sections 141 and 142 of the General Corporation Law of the State of Delaware, significant authority with respect to the management of the Company has

Form of Restricted Stock Unit Agreement – Non-Employee Director (filed as Exhibit 10.16 to our current report on Form 8-K on March 18, 2016, and incorporated herein by reference)†

Exhibit 10.16 NUVECTRA CORPORATION 2016 EQUITY INCENTIVE PLAN FORM OF RESTRICTED STOCK UNIT AGREEMENT ? NON-EMPLOYEE DIRECTORS This Restricted Stock Unit Agreement (this ?Agreement?) is made and entered into as of the date of grant set forth below (the ?Date of Grant?) by and between Nuvectra Corporation, a Delaware corporation (the ?Company?), and the individual named below (?Grantee?). Capitaliz